11c-mci
Phase 1
11c-mci is one of 13 therapeutic programs targeting Depression. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
14 competitors in Depression
#DrugCompanyPhaseTrials
1Brintellix
TakedaApproved
Vraylar
AbbVieApproved
Ulotaront
IIntra-Cellular Therapies, Inc.
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Ketalar
Boehringer IngelheimPhase 2
Glucophage
EMD SeronoPhase 2
Clemastine Fumarate
NovartisPhase 2
Psilocybin
COMPASS PathwaysPhase 2
Otezla
AmgenPhase 1
18f-Pf-06445974
NNational Institute of Mental Health (NIMH)
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 11c-mci. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]